Edatrexate
Modify Date: 2024-01-08 14:43:34
Edatrexate structure
|
Common Name | Edatrexate | ||
|---|---|---|---|---|
| CAS Number | 80576-83-6 | Molecular Weight | 467.47800 | |
| Density | 1.441 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H25N7O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EdatrexateEdatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck[1][2]. |
| Name | 2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Edatrexate (0.14 g/kg and 0.21 g/kg; i.p.; twice weekly×3 or weekly×3) exerts potent efficacy against advanced metastatic disease in tumor-bearing mice, better than MTX[1]. Animal Model: Murine models of advanced metastatic disease (including E0771 mammary adenocarcinoma, T241 fibrosarcoma, Lewis lung carcinoma, B16 melanoma, or C38 colon carcinoma)[2] Dosage: 0.14 g/kg and 0.21 g/kg Administration: Intraperitoneal injection; 0.14 g/kg twice weekly for 3 weeks and 0.21 g/kg weekly for 3 weeks; added Ca leucovorin (LCV) 16, 20, 24 h after Edatrexate treatment Result: Increased survival of tumor-bearing mice. Showed markedly therapeutic effectiveness against advanced metastatic disease in high-dose regimen with delayed LCV rescue. |
| Density | 1.441 g/cm3 |
|---|---|
| Molecular Formula | C22H25N7O5 |
| Molecular Weight | 467.47800 |
| Exact Mass | 467.19200 |
| PSA | 207.30000 |
| LogP | 2.92160 |
| Index of Refraction | 1.686 |
|
~88%
Edatrexate CAS#:80576-83-6 |
| Literature: Piper; Johnson; Otter; Sirotnak Journal of Medicinal Chemistry, 1992 , vol. 35, # 16 p. 3002 - 3006 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 16 p. 3002 - 3006 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 10 p. 1227 - 1230 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 10 p. 1227 - 1230 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 10 p. 1227 - 1230 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 10 p. 1227 - 1230 |
|
~%
Edatrexate CAS#:80576-83-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 35, # 16 p. 3002 - 3006 |
![methyl 4-[2-(2,4-diamino-6-pteridinyl)-1-ethylethenyl]benzoate structure](https://www.chemsrc.com/caspic/399/151071-45-3.png)
![4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoic acid structure](https://www.chemsrc.com/caspic/177/80576-81-4.png)
| 10-EdAM |
| 10-ethyl-10-deazaaminopterin |
| EDATREXATE |